# A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

> **NCT07312851** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 186 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Andexanet alfa
- **DRUG:** Rivaroxaban
- **DRUG:** Apixaban
- **DRUG:** Enoxaparin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07312851
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2026-06-19
- **Final completion:** 2026-06-19
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07312851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07312851, "A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07312851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*